Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: SELL (auto-tracking)
0.00% $0.319
America/New_York / 4 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 34.47 mill |
EPS: | -0.820 |
P/E: | -0.390 |
Earnings Date: | Mar 25, 2024 |
SharesOutstanding: | 108.06 mill |
Avg Daily Volume: | 0.960 mill |
RATING 2024-04-03 |
---|
B+ |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Neutral | |
P/E: | Neutral | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | ||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.390 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.07x |
Company: PE -0.390 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.694 (117.51%) $0.375 |
Date: 2024-03-23 |
Expected Trading Range (DAY) |
---|
$ 0.0795 - 0.486 ( +/- 71.86%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-02 | Gu Ehong | Sell | 1 731 | Ordinary Shares |
2024-04-09 | Gu Ehong | Sell | 17 889 | Ordinary Shares |
2024-02-15 | Poukalov Konstantin | Buy | 36 300 | Ordinary Shares |
2024-02-15 | Poukalov Konstantin | Sell | 19 218 | Ordinary Shares |
2024-02-15 | Poukalov Konstantin | Sell | 36 300 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
71.30 |
Last 79 transactions |
Buy: 50 859 501 | Sell: 7 434 951 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.319 (0.00% ) |
Volume | 2.48 mill |
Avg. Vol. | 0.960 mill |
% of Avg. Vol | 258.20 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:15 | sell | $4.08 | N/A | Active |
---|
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor for ulcerative colitis and Crohn's disease; NX-13 for ulcerative colitis; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03, an eye solution for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.